• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

《KDIGO 慢性肾脏病-矿物质和骨异常(CKD-MBD)指南的推荐:欧洲肾脏最佳实践(ERBP)评论声明》

Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement.

机构信息

King's Health Partners, Guy's Campus, London SE1 9RT, UK.

出版信息

Nephrol Dial Transplant. 2010 Dec;25(12):3823-31. doi: 10.1093/ndt/gfq513. Epub 2010 Sep 9.

DOI:10.1093/ndt/gfq513
PMID:20829401
Abstract

Under the auspices of the European Renal Best Practice, a group of European nephrologists, not serving on the Kidney Disease Improving Global Outcomes (KDIGO) working group, but with significant clinical and research interests and expertise in these areas, was invited to examine and critique the Chronic Kidney Disease-Mineral and Bone Disorder KDIGO document published in August 2009. The final form of this paper in Nephrology Dialysis Transplantation, as a commentary, not as a position statement, reflects the fact that we have had no more evidence to review, discuss and debate available to us than was available to the KDIGO working group. However, we have felt that we were able to comment on specific areas where we feel that further clinical guidance would be helpful, thereby going beyond the KDIGO position as reflected in their document. This present paper, we hope, will be of most use to the practising kidney specialist and those allied to the clinical team.

摘要

在欧洲肾脏最佳实践的主持下,一组欧洲肾病学家受邀对 2009 年 8 月发表的慢性肾脏病-矿物质和骨异常肾脏病改善全球结局(KDIGO)文件进行检查和评论,他们没有参与 KDIGO 工作组,但在这些领域具有重要的临床和研究兴趣和专业知识。这篇论文最终以评论的形式发表在《肾脏病与透析移植》上,而不是作为立场声明,这反映了一个事实,即我们所能审查、讨论和辩论的证据与 KDIGO 工作组可用的证据一样多。然而,我们认为,我们能够对我们认为需要进一步临床指导的具体领域发表评论,从而超越 KDIGO 在其文件中反映的立场。我们希望,本文件对从事肾脏专业的医生和临床团队的相关人员最有用。

相似文献

1
Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement.《KDIGO 慢性肾脏病-矿物质和骨异常(CKD-MBD)指南的推荐:欧洲肾脏最佳实践(ERBP)评论声明》
Nephrol Dial Transplant. 2010 Dec;25(12):3823-31. doi: 10.1093/ndt/gfq513. Epub 2010 Sep 9.
2
Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) guidelines on kidney transplantation: a European Renal Best Practice (ERBP) position statement.支持肾脏病改善全球结局组织(KDIGO)关于肾移植的指南:欧洲肾脏最佳实践(ERBP)立场声明。
Nephrol Dial Transplant. 2011 Jul;26(7):2099-106. doi: 10.1093/ndt/gfr169. Epub 2011 May 9.
3
Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) hepatitis C guidelines: a European Renal Best Practice (ERBP) position statement.认可《改善全球肾脏病预后组织(KDIGO)丙型肝炎指南》:欧洲肾脏最佳实践(ERBP)立场声明。
Nephrol Dial Transplant. 2009 Mar;24(3):719-27. doi: 10.1093/ndt/gfn608. Epub 2009 Feb 8.
4
KDIGO CKD-MBD Discussion forum: the Brazilian perspective.改善全球肾脏病预后组织慢性肾脏病-矿物质和骨异常讨论论坛:巴西视角
J Bras Nefrol. 2010 Jul-Sep;32(3):229-36.
5
[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). KDIGO CKD-MBD Clinical Practice Guideline].[慢性肾脏病-矿物质和骨异常(CKD-MBD)。KDIGO慢性肾脏病-矿物质和骨异常临床实践指南]
Clin Calcium. 2010 Jul;20(7):1021-7.
6
[The new Kidney Disease: Improving Global Outcomes (KDIGO) guideline for the mineral and bone disorder associated with chronic kidney disease (MBD-CKD)].[新版《肾脏病:改善全球预后(KDIGO)慢性肾脏病矿物质和骨异常指南(MBD-CKD)》]
Nephrol Ther. 2010 Jun;6(3):149-50. doi: 10.1016/j.nephro.2010.01.001. Epub 2010 Feb 25.
7
KDOQI US commentary on the KDIGO clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in CKD.美国肾脏疾病改善全球预后组织(KDOQI)对改善全球肾脏病预后组织(KDIGO)慢性肾脏病丙型肝炎预防、诊断、评估及治疗临床实践指南的评论
Am J Kidney Dis. 2008 Nov;52(5):811-25. doi: 10.1053/j.ajkd.2008.08.005.
8
Canadian Society of Nephrology commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD).加拿大肾脏病学会对2009年改善全球肾脏病预后组织(KDIGO)慢性肾脏病-矿物质和骨异常(CKD-MBD)诊断、评估及治疗临床实践指南的评论。
Am J Kidney Dis. 2010 May;55(5):800-12. doi: 10.1053/j.ajkd.2010.02.339.
9
[The French clinician's guide to the Kidney disease: Improving global outcomes (KDIGO) for chronic kidney disease-mineral and bone disorders (CKD-MBD)].[法国临床医生慢性肾脏病矿物质和骨异常(CKD-MBD)改善全球肾脏病预后组织(KDIGO)指南]
Nephrol Ther. 2010 Jun;6(3):151-7. doi: 10.1016/j.nephro.2009.12.003. Epub 2010 Apr 15.
10
Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement.肾脏病:改善全球肾脏病预后组织关于慢性肾脏病贫血管理的指南:欧洲肾脏病最佳实践的立场声明。
Nephrol Dial Transplant. 2013 Jun;28(6):1346-59. doi: 10.1093/ndt/gft033. Epub 2013 Apr 12.

引用本文的文献

1
The effects of dialysate calcium prescription on mortality outcomes in incident patients on hemodialysis.透析液钙处方对新接受血液透析患者死亡率的影响。
Clin Kidney J. 2024 Oct 4;17(10):sfae288. doi: 10.1093/ckj/sfae288. eCollection 2024 Oct.
2
The Impact of Cholecaciferol Supplementation on Bone Mineral Density in Long-Term Kidney Transplant Recipients.维生素 D 补充对长期肾移植受者骨密度的影响。
Biomolecules. 2023 Mar 31;13(4):629. doi: 10.3390/biom13040629.
3
Serum Phosphorus Level Rises in US Hemodialysis Patients Over the Past Decade: A DOPPS Special Report.
过去十年美国血液透析患者血清磷水平上升:一项DOPPS特别报告。
Kidney Med. 2022 Dec 14;5(2):100584. doi: 10.1016/j.xkme.2022.100584. eCollection 2023 Feb.
4
Global Dialysis Perspective: Kuwait.全球透析视角:科威特
Kidney360. 2021 Apr 7;2(6):1015-1020. doi: 10.34067/KID.0000392021. eCollection 2021 Jun 24.
5
Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in chronic kidney disease: translational opportunities and challenges.神经肽 Y 作为慢性肾脏病中心血管疾病和认知功能障碍的危险因素:转化机会和挑战。
Nephrol Dial Transplant. 2021 Dec 28;37(Suppl 2):ii14-ii23. doi: 10.1093/ndt/gfab284.
6
Evidence in chronic kidney disease-mineral and bone disorder guidelines: is it time to treat or time to wait?慢性肾脏病 - 矿物质和骨异常指南中的证据:是该治疗的时候了还是该等待的时候了?
Clin Kidney J. 2020 Jan 25;13(4):513-521. doi: 10.1093/ckj/sfz187. eCollection 2020 Aug.
7
Effects of the dialysate calcium concentrations and mineral bone disease treatments on mortality in The French Renal Epidemiology and Information Network (REIN) registry.法国肾脏流行病学与信息网络(REIN)登记处中透析液钙浓度及矿物质骨病治疗对死亡率的影响。
PLoS One. 2020 Jul 6;15(7):e0235135. doi: 10.1371/journal.pone.0235135. eCollection 2020.
8
Benefit-risk balance of native vitamin D supplementation in chronic hemodialysis: what can we learn from the major clinical trials and international guidelines?慢性血液透析患者应用维生素 D 治疗的获益-风险平衡:从主要临床试验和国际指南中我们能学到什么?
Ren Fail. 2019 Nov;41(1):607-615. doi: 10.1080/0886022X.2019.1632719.
9
Complications of chronic kidney disease: current state, knowledge gaps, and strategy for action.慢性肾脏病的并发症:现状、知识空白及行动策略
Kidney Int Suppl (2011). 2017 Oct;7(2):122-129. doi: 10.1016/j.kisu.2017.07.007. Epub 2017 Sep 20.
10
Achievement of 2009 and 2017 Kidney Disease: Improving Global Outcomes mineral and bone targets and survival in a French cohort of chronic kidney disease Stages 4 and 5 non-dialysis patients.2009年和2017年慢性肾脏病的成就:法国慢性肾脏病4期和5期非透析患者队列中改善全球肾脏病预后组织矿物质和骨指标及生存率的情况
Clin Kidney J. 2018 Oct;11(5):710-719. doi: 10.1093/ckj/sfy015. Epub 2018 Mar 15.